VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

• Autores principales: Sarah Low (Autor), Haixia Wu (Autor), Kavita Jerath (Autor), Annette Tibolla (Autor), Birgit Fogal (Autor), Rebecca Conrad (Autor), Deborah Webb (Autor), Margit MacDougall (Autor), Steven Kerr (Autor), Valentina Berger (Autor), Rajvee Dave (Autor), Jorge Villalona (Autor), Lynn Pantages (Autor), Jennifer Ahlberg (Autor), Hua Li (Autor), Diane Van Hoorick (Autor), Cedric Ververken (Autor), John Broadwater (Autor), Alisa Waterman (Autor), Sanjaya Singh (Autor), Rachel Kroe-Barrett (Autor)
• Formato: Libro
• Publicado: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified. Here we describe the lead finding and engineering approach that lead to the identificatio...